Literature DB >> 5570853

Amantadine hydrochloride treatment of tardive dyskinesia.

B L Decker, J M Davis, D S Jonowsky, M K el-Yousef, H J Sekerke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5570853     DOI： 10.1056/NEJM197110072851516

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Rapid response of disabling tardive dyskinesia to amantadine: a case report.

Authors:  Gaurav Jain
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Dystonia and leveraging oral pharmacotherapy.

Authors:  Michelle Ann C Sy; Hubert H Fernandez
Journal:  J Neural Transm (Vienna)       Date:  2021-04-20       Impact factor: 3.575

Review 4.  Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.

Authors:  R M Kobayashi
Journal:  West J Med       Date:  1976-10

Review 5.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.

Authors:  Jungjin Kim; Eric Macmaster; Thomas L Schwartz
Journal:  Drugs Context       Date:  2014-04-09

Review 7.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.